Effekte von Leitlinien

Archiv für November 2008

[Guidelines and recommendations in anesthesiology and intensive care medicine.]

Donnerstag, 06. November 2008

< ![CDATA[

[Guidelines and recommendations in anesthesiology and intensive care medicine.]

Anaesthesist. 2008 Oct 19;

Authors: Kaisers U

PMID: 18931981 [PubMed - as supplied by publisher]

]]>

[Assessment of "Contrat de bon usage" on 4 Years Period: Conformity to Guidelines - Experience of Anti-TNFalpha.]

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

[Assessment of "Contrat de bon usage" on 4 Years Period: Conformity to Guidelines - Experience of Anti-TNFalpha.]

Therapie. 2008 Jul-Aug;63(4):281-9

Authors: Plard C, Serry G, Faure P, Madelaine-Chambrin I

Objective: To evaluate the evolution of anti-TNFalpha prescriptions in relation with the “contrat de bon usage” between 2004 and 2007.Method: All the infliximab, etanercept and adalimumab prescriptions were studied over the first six month period of each year between 2004 and 2007. The indications were compared with the guidelines for therapeutic use.Results: One thousand one hundred and ninety nine prescriptions were analysed. The number of validated prescriptions increased each year. The percentage of “good use” infliximab prescriptions increased from 68.4% to 98.5% from 2004 to 2007. All etanercept prescriptions corresponded to the validated indication group whereas the adalimumab prescriptions fluctuated from 100% to 75%. Few indications were prescribed apart from the guidelines (sarcoidosis, acute graft versus host disease and histiocytosis).Conclusion: The use of anti-TNFalpha drugs has progressed over the last 4 years, in accordance with the “contrat de bon usage”. This is due to a better knowledge of these drugs, a good evolution of guidelines and the active participation of the medical team in the “contrat de bon usage” plan.Objectif : Evaluer l’évolution des prescriptions d’anti-TNFalpha (Tumor Necrosis Factor alpha) dans le cadre du respect du CBUS (contrat de bon usage) entre 2004 et 2007.Méthodes : Toutes les prescriptions d’infliximab, d’étanercept et d’adalimumab des premiers semestres de 2004 à 2007 ont été étudiées. Les indications ont été analysées selon les groupes d’indications des référentiels en vigueur. Résultats : Mille cent quatre-vingt-dix-neuf ordonnances ont été analysées. Les indications reconnues ont progressé au cours du temps. Pour l’infliximab, elles sont passées de 68,4 % en 2004 à 98,5 % en 2007. Les prescriptions d’étanercept n’ont concerné que des indications reconnues et celles de l’adalimumab ont varié de 100 % à 75 %. Certaines indications ont perduré hors référentiel validé (sarcoïdose, maladie du greffon contre l’hôte et histiocytose). Conclusion : Les prescriptions d’anti-TNFalpha ont évolué favorablement au cours du temps, respectant de mieux en mieux le CBUS. Ceci est dû à une meilleure connaissance de ces médicaments, à une évolution pertinente des recommandations et des indications et à l’implication des professionnels de santé dans la mise en place du CBUS.

PMID: 18937906 [PubMed - in process]

]]>

Translation of evidence-based guidelines in preventive cardiology: the EUROACTION program.

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

Translation of evidence-based guidelines in preventive cardiology: the EUROACTION program.

Nat Clin Pract Cardiovasc Med. 2008 Oct 21;

Authors: Pearson TA

The report from the EUROACTION Study Group demonstrates that a nurse-coordinated, multidisciplinary, family-based program results in improvements in patients’ lifestyle, control of blood pressure, and use of cardioprotective drugs, when compared with standard care. The results of the study support the need for organized and systematic approaches to individualized cardiovascular risk reduction in patients with, or at high risk for, coronary heart disease. The EUROACTION program is an example of effectiveness research, which aims to develop and validate strategies to implement interventions previously shown to be efficacious.

PMID: 18941437 [PubMed - as supplied by publisher]

]]>

[Interdisciplinary and Evidence-based Treatment Guideline for Juvenile Idiopathic Arthritis.]

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

[Interdisciplinary and Evidence-based Treatment Guideline for Juvenile Idiopathic Arthritis.]

Klin Padiatr. 2008 Nov-Dec;220(6):392-402

Authors: Guellac N, Niehues T

Treatment of Juvenile Idiopathic Arthritis (JIA) has improved quality of life in children and adolescents suffering from JIA. However, it varies considerably from caregiver to caregiver. Therefore a standardisation of care on the basis of consensus treatment recommendations offers the chance to further improve the quality of care for children and adolescents with JIA. We aimed to establish an interdisciplinary, evidence-based treatment guideline for JIA based on the existing guideline from 2005. METHODS: We did a systematic literature analysis in PUBMED with the key words “juvenile idiopathic (rheumatoid) arthritis” and “therapy”. As limits in PUBMED we used: humans, published in the last 3 years, all child 0-18 years, clinical trial. Studies relating to diagnosis of JIA, Uveitis, vaccination, transition and rofexocibe were excluded. Authors of the 2005 guideline and representatives nominated by different societies were invited to attend the consensus conferences which were hosted by a professional moderator. Following societies were invited: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Consensus conferences took place in Düsseldorf on May 9th and August 1st 2007 and were each attended by more than 95% of the nominated representatives Finally, statements were confirmed in a Delphi method. RESULTS AND CONCLUSION: Consensus statements regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (EBM).

PMID: 18949678 [PubMed - in process]

]]>

[Significance of the legal liability of guidelines from specialist medical societies.]

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

[Significance of the legal liability of guidelines from specialist medical societies.]

Anaesthesist. 2008 Oct 26;

Authors: Kuwatsch S

PMID: 18953518 [PubMed - as supplied by publisher]

]]>

Development of evidence-based clinical practice guidelines (CPGs): comparing approaches.

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

Development of evidence-based clinical practice guidelines (CPGs): comparing approaches.

Implement Sci. 2008 Oct 27;3(1):45

Authors: Turner T, Misso M, Harris C, Green S

ABSTRACT: BACKGROUND: While the potential of clinical practice guidelines (CPGs) to support implementation of evidence has been demonstrated, it is not currently being achieved. CPGs are both poorly developed and ineffectively implemented. To improve clinical practice and health outcomes, both well developed CPGs and effective methods of CPG implementation are needed. We sought to establish whether there is agreement on the fundamental characteristics of an evidence-based CPG development process and to explore whether the level of guidance provided in CPG development handbooks is sufficient for people using these handbooks to be able to apply it. METHODS: CPG development handbooks were identified through a broad search of published and grey literature. Documents published in English produced by national or international organisations purporting to support development of evidence-based CPGs were included. A list of 14 key elements of a CPG development process was developed. Two authors read each handbook. For each handbook a judgement was made as to how it addressed each element; assigned as either ‘mentioned and clear guidance provided’; ‘mentioned but limited practical detail provided’; or ‘not mentioned’. RESULTS: Six CPG development handbooks were included. These were produced by the Council of Europe, the National Health and Medical Research Council of Australia, the National Institute for Health and Clinical Excellence in the UK, the New Zealand Guidelines Group, the Scottish Intercollegiate Guideline Network and the World Health Organization. There was strong concordance between the handbooks on the key elements of an evidence-based CPG development process. All six of the handbooks require and provide guidance on establishment of a multidisciplinary guideline development group, involvement of consumers, identification of clinical questions or problems, systematic searches for and appraisal of research evidence, a process for drafting recommendations, consultation with others beyond the guideline development group and ongoing review and updating of the CPG. CONCLUSIONS: The key elements of an evidence-based CPG development process are addressed with strong concordance by existing CPG development handbooks. Further research is required to determine why these key elements are often not addressed by CPG developers.

PMID: 18954465 [PubMed - as supplied by publisher]

]]>

Recommendations for the implementation of Joint Commission guidelines for labeling medications.

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

Recommendations for the implementation of Joint Commission guidelines for labeling medications.

J Vasc Interv Radiol. 2008 Nov;19(11):1531-5

Authors: Statler JD, Towbin RB, Ronsivalle JA, Oteham A, Miller DL, Grassi CJ, Brown DB, D’Agostino HR, Khan AA, Kundu S, Roberts AC, Saiter CK, Schwartzberg MS, Vedantham S, Wallace MJ, Cardella JF,

PMID: 18954764 [PubMed - in process]

]]>

American College of Surgeons Guidelines Program: a process for using existing guidelines to generate best practice recommendations for central venous access.

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

American College of Surgeons Guidelines Program: a process for using existing guidelines to generate best practice recommendations for central venous access.

J Am Coll Surg. 2008 Nov;207(5):676-82

Authors: Freel AC, Shiloach M, Weigelt JA, Beilman GJ, Mayberry JC, Nirula R, Stafford RE, Tominaga GT, Ko CY,

BACKGROUND: Many professional organizations help their members identify and use quality guidelines. Some of these efforts involve developing new guidelines, and others assess existing guidelines for their clinical usefulness. The American College of Surgeons Guidelines Program attempts to recognize useful surgical guidelines and develop research questions to help clarify existing clinical guidelines. We used existing guidelines about central venous access to develop a set of summary recommendations that could be used by practitioners to establish local best practices. STUDY DESIGN: A comprehensive literature search identified existing clinical guidelines for short-term central venous access. Two reviewers independently rated the guidelines using the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument. Highly scored guidelines were analyzed for content, and their recommendations were compiled into a summary table. The summary table was reviewed by an independent panel of experts for clinical utility. RESULTS: Thirty-two guidelines were identified, and 23 met inclusion criteria. The AGREE rating resulted in four guidelines that were strongly recommended and five that were recommended with alterations. Three comprehensive tables of recommendations were produced: procedural, maintenance, and infectious assessment. A panel of experts came to consensus agreement on the final format of the best practice recommendations, which included 30 summary recommendations. CONCLUSIONS: Our process combined assessing existing guidelines methodology with expert opinion to produce a best practice list of guidelines that could be fashioned into local care routines by practicing physicians. The American College of Surgeons guidelines program believes this process will help validate the clinical utility of existing guidelines and identify areas needing further investigation to determine practical validity.

PMID: 18954779 [PubMed - in process]

]]>

Clinical Practice Guidelines for Improving Outcomes in Sepsis.

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

Clinical Practice Guidelines for Improving Outcomes in Sepsis.

Heart Lung Circ. 2008 Oct 27;

Authors: Ihle BU

Sepsis is a common medical condition resulting from an infectious stimulus with a variable inflammatory response leading to a spectrum of clinical conditions from mild constitutional symptoms to varying degrees of organ dysfunction and death. The understanding of the patho-physiology of sepsis has lead to better treatment modalities and whilst sepsis is an increasingly more common condition world wide, the mortality from sepsis is nevertheless falling. Treatment algorithms have been promulgated over the years and levels of evidence for these have varied. This review will focus on the early management issues recently updated and released by a multi-national panel of experts based on best evidence, aimed at reducing sepsis related mortality by 25%.

PMID: 18964253 [PubMed - as supplied by publisher]

]]>

KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD.

Donnerstag, 06. November 2008

< ![CDATA[

Related Articles

KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD.

Am J Kidney Dis. 2008 Nov;52(5):811-25

Authors: Gordon CE, Balk EM, Becker BN, Crooks PA, Jaber BL, Johnson CA, Michael MA, Pereira BJ, Uhlig K, Levin A

KDIGO (Kidney Disease: Improving Global Outcomes) is an international initiative with a key mission of developing clinical practice guidelines in the area of chronic kidney disease (CKD). KDIGO recently published evidence-based clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus infection in individuals with CKD. The process of adaptation of international guidelines is an important task that, although guided by general principles, needs to be individualized for each region and country. Therefore, the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (KDOQI) convened a multidisciplinary group to comment on the application and implementation of the KDIGO guidelines for patients with CKD in the United States. This commentary summarizes the process undertaken by this group in considering the guidelines in the context of health care delivery in the United States. Guideline statements are presented, followed by a succinct discussion and annotation of the rationale for the statements. Research recommendations that are of particular interest to the United States are then summarized to highlight future areas of inquiry that would enable updating of the guidelines.

PMID: 18971009 [PubMed - in process]

]]>

  Related Articles